TriSalus Life Sciences (TLSI) to Release Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will release its earnings data before the market opens on Thursday, November 14th. Analysts expect TriSalus Life Sciences to post earnings of ($0.37) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $7.36 million during the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Trading Up 4.0 %

TLSI stock opened at $4.16 on Thursday. The company has a market cap of $121.93 million, a PE ratio of -1.66 and a beta of 0.49. The stock has a 50-day moving average price of $4.46 and a two-hundred day moving average price of $6.05. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42.

Analyst Upgrades and Downgrades

Several research firms recently commented on TLSI. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price on the stock. Finally, Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $12.50.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.